Exact Sciences (EXAS) — Customer Relationships and Commercial Footprint

Exact Sciences operates a vertically integrated diagnostics business that sells laboratory testing services (Cologuard, Oncotype, others) directly to patients and through payer and provider contracts, while expanding access through distribution and blood-collection partnerships. The company monetizes via test payments from payers (Medicare, commercial insurers), patient-billed receipts, and fee-for-service laboratory revenue, with international distribution for select products. For deeper, machine-parsable exposure mapping visit https://nullexposure.com/.

Investment thesis — what the customer book tells investors

Exact Sciences’ commercial strength rests on large payer contracts and national access points, combined with an entrenched Medicare revenue base and strategic partnerships that extend specimen collection. That structure delivers predictable revenue per test but creates concentration risk toward large payers and regulatory reimbursement regimes, and operational dependence on third-party collection and distribution partners.

The customer and partner map — line-by-line takeaways

Below are concise, source-linked summaries for every named relationship identified in the company materials and related reporting.

Centers for Medicare & Medicaid Services (CMS)

Exact’s payment terms are directly influenced by CMS coverage and reimbursement decisions, reflecting Medicare’s outsized role in the business model. According to Exact Sciences’ FY2025 Form 10‑K, CMS coverage materially affects payment terms and revenue timing (FY2025 10‑K).

UnitedHealthcare

UnitedHealthcare accounted for 13% of revenue in FY2025, making it one of Exact’s top commercial payers and a material cash flow contributor. This breakdown is reported in the company’s FY2025 10‑K (FY2025 10‑K).

Aetna (CVS Health / Aetna)

Exact announced contract wins with Aetna in Q3 2025 to add Cologuard Plus for members, expanding commercial access through a top-ten payer. Management disclosed this on the Q3 2025 earnings call (EXAS Q3 2025 earnings call).

CVS

CVS (Aetna under the CVS umbrella in disclosure) is noted alongside Aetna for new Cologuard Plus contracts in Q3 2025, reinforcing distribution into large integrated payer–provider channels (EXAS Q3 2025 earnings call).

Highmark

Highmark signed contracts in Q3 2025 to bring Cologuard Plus to its members, representing another major payer expansion for Exact’s colorectal screening product (EXAS Q3 2025 earnings call).

Humana

Exact credited the sales team for securing favorable contracts with Humana that increase access to Cologuard Plus, a deal highlighted on the Q2 2025 earnings call and characterized as expanding coverage for millions of members (EXAS Q2 2025 earnings call).

Centene

Centene is the other large commercial payer named with Humana; Exact’s Q2 2025 commentary states that Humana and Centene together represent about 40 million members reached through recent commercial agreements (EXAS Q2 2025 earnings call).

Quest Diagnostics (DGX)

Exact entered an agreement with Quest Diagnostics to enable blood collection at roughly 7,000 patient access sites across the U.S., materially expanding specimen collection infrastructure for blood-based assays (FY2025 10‑K).

Freenome Holdings, Inc.

Exact has an exclusive license agreement with Freenome, a strategic licensing arrangement disclosed in Exact’s FY2025 10‑K that affects product rights or technology commercialization (FY2025 10‑K).

MDxHealth (MDXH)

MDxHealth amended an earn-out tied to its GPS acquisition from Exact Sciences, lowering and deferring roughly $20 million of payment, a change reported across press coverage as a near-term cash-flow adjustment between the two firms (Globe and Mail; MarketBeat; FY2026 press coverage).

Privia Health (PRVA)

Exact supported a Privia Health‑led colorectal cancer screening program that achieved high screening rates via collaboration, as reported in a March 2026 press release highlighting Exact’s role in population-level screening initiatives (Biospace press release, March 2026).

Abbott (ABT)

Financial press reported that Abbott announced a proposed acquisition of Exact Sciences for up to $23 billion, a strategic outcome with obvious implications for Exact’s customer relationships and integration into a large diagnostics platform (CNBC, Nov 20, 2025).

NEO (competitor mention)

A FY2024 filing from NEO lists Exact Sciences among direct competitors in molecular diagnostics and liquid biopsy spaces, positioning Exact within a competitive set that includes Guardant, Natera, and others, which frames market-share risk and pricing pressure (NEO FY2024 10‑K).

How these relationships translate into operating constraints

The filings and calls surface multiple company‑level signals that define Exact’s operating model:

• Contracting posture: Exact balances negotiated payer contracts (Medicare, large commercial insurers) with direct patient billing; payers drive remittance timing and pricing, while patients are the ultimate purchasers without formal contracts. This mix creates both predictable recurring cash from contracted payers and variability from patient billing.
• Concentration and criticality: Medicare and a handful of large payers are material—CMS accounted for ~15% of revenue and UnitedHealthcare ~13% in FY2025—so reimbursement policy and commercial contract renewals are high‑impact events for revenues.
• Channel structure: The company uses third‑party access (Quest Diagnostics’ 7,000 sites) and international distributors for Oncotype outside the U.S., which scales access but allocates execution risk to partners.
• Customer types and geography: The business sells to individual patients, government payers, and large enterprises (payers and health systems). Cologuard is U.S.-centric, while Oncotype has substantial international distribution.
• Maturity and role diversity: Relationships span active distributor agreements, buyer/payer contracts, and licensing deals (e.g., Freenome), reflecting a mix of mature revenue streams (Cologuard, Oncotype) and strategic tech partnerships.

Key risks and opportunity levers

• Risk — reimbursement concentration: Medicare and a few large payers account for a disproportionate share of revenue, exposing EXAS to policy changes or adverse coverage decisions.
• Risk — partner execution: Reliance on third‑party collection/distribution (Quest, international distributors) introduces operational dependencies that affect throughput and cost.
• Opportunity — new payer contracts: Recent Aetna, Highmark, Humana, and Centene agreements materially increase commercial access and underpin near‑term revenue growth from Cologuard Plus.
• Opportunity — strategic M&A and licensing: The Abbott acquisition proposal and licensing deals (Freenome) signal potential scale benefits and technology diversification.

For a consolidated view of counterparties, contracts, and exposure analytics tailored to institutional investors and operators, see our mapping and monitoring tools at https://nullexposure.com/.

Bold takeaway: Exact Sciences is a payer‑dependent, partnership‑enabled diagnostics platform — commercial wins with large insurers and expanded collection agreements are the primary levers for revenue growth, while Medicare and partner concentration represent the principal downside exposure.